Weight Loss (WL) With Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Correlates With Improvements in Liver Function in Overweight/Obese Adults With Elevated Alanine Aminotransferase (ALT)

被引：0

|

作者：

Klein, Samuel

Najarian, Thomas

Troupin, Barbara

Day, Wesley W.

机构：

来源：

OBESITY | 2011年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：S177 / S177

页数：1

相关论文

共 37 条

[21] Weight Loss with Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Reverses Metabolic Syndrome (MetS) and Improves Associated Traits
Garvey, W. Timothy
Henry, Robert R.
Peterson, Craig A.
Bowden, Charles H.
DIABETES, 2011, 60 : A506 - A506
[22] Weight Loss (WL) by Degree of Comorbidity as Assessed by the Edmonton Obesity Staging System (EOSS) in Subjects Receiving Controlled-Release Phentermine/Topiramate (PHEN/TPM CR)
Sharma, Arya M.
Padwal, Raj S.
Day, Wesley W.
DIABETES, 2012, 61 : A516 - A516
[23] Once-daily, controlled-release phentermine/topiramate (PHEN/TPM CR) results in significant weight loss and risk factor improvement in overweight/obese subjects over 56 weeks
Aronne, L. J.
Troupin, B.
Day, W. W.
DIABETES OBESITY & METABOLISM, 2010, 12 : 51 - 52
[24] A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients with Type 2 Diabetes Mellitus (T2DM) or Prediabetes
Gadde, Kishore
Najarian, Thomas
Day, Wesley W.
DIABETES, 2010, 59 : A101 - A101
[25] CARDIOVASCULAR EFFECTS BASED ON MAGNITUDE OF WEIGHT LOSS (WL) IN OBESE/OVERWEIGHT SUBJECTS WITH HYPERTENSION RECEIVING PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER)
Bakris, George
Davidson, Michael H.
Gupta, Alok K.
JOURNAL OF CLINICAL HYPERTENSION, 2013, 15 (07): : 517 - 517
[26] Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) and Markers of Type 2 Diabetes Mellitus (T2DM)
Ryan, Donna H.
Gadde, Kishore
Troupin, Barbara
Tam, Peter
DIABETES, 2010, 59 : A482 - A482
[27] Once-daily, low-dose, controlled-release phentermine/topiramate results in significant clinical improvements in overweight/obese patients with type 2 diabetes
Garvey, W. T.
Troupin, B.
Day, W. W.
DIABETOLOGIA, 2010, 53
[28] Weight Loss (WL) With Phentermine and Topiramate Extended-Release (PHEN/TPM ER) and Change in Glycemic Parameters in Overweight and Obese Adults With Dysglycemia and Stratified by Baseline Body Mass Index (BMI)
Ryan, Donna H.
Bowden, Charles H.
DIABETES, 2013, 62 : A540 - A540
[29] Effects of Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) on Weight, Glycemic Markers, and Progression to Type 2 Diabetes Mellitus (T2DM)
Ryan, Donna H.
Gadde, Kishore
Wilson, Leland F.
Troupin, Barbara
DIABETES, 2010, 59 : A491 - A491
[30] EFFECT OF WEIGHT LOSS (WL) ON CONCOMITANT MEDICATION COSTS IN OBESE/OVERWEIGHT INDIVIDUALS WITH METABOLIC SYNDROME (METS) RECEIVING PHENTERMINE/TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER)
Kahan, S.
Karnawat, S.
VALUE IN HEALTH, 2015, 18 (03) : A297 - A297

← 1 2 3 4 →